CD161 (human NKR-P1A) signaling in NK cells involves the activation of acid sphingomyelinase

Journal of Immunology

Volumn 176, Issue 4, 2006, Pages 2397-2406

  Pozo, David ^a   Valés Gómez, Mar ^a   Mavaddat, Nasim ^a   Williamson, Sharon C ^a   Chisholm, Susan E ^a   Reyburn, Hugh ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD161 ANTIGEN; CERAMIDE; MONOCLONAL ANTIBODY; SPHINGOMYELIN PHOSPHODIESTERASE;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; CROSS LINKING; ENZYME ACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INNATE IMMUNITY; NATURAL KILLER CELL; NATURAL KILLER T CELL; PRIORITY JOURNAL; SECOND MESSENGER; SIGNAL TRANSDUCTION; TWO HYBRID SYSTEM;

EID: 32044439625     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.4.2397     Document Type: Article

References (68)

1. Chambers, W., N. Vujanovic, A. DeLeo, M. Olszowy, R. Herberman, and J. Hiserodt. 1989. Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells. J. Exp. Med. 169: 1373-1389.
2. 2+-dependent mechanism. J. Exp. Med. 186: 467-472.
3. Plougastel, B., K. Matsumoto, C. Dubbelde, and W. M. Yokoyama. 2001. Analysis of a 1-Mb BAC contig overlapping the mouse Nkrp1 cluster of genes: cloning of three new Nkrp1 members, Nkrp1d, Nkrp1e, and Nkrp1f. Immunogenetics 53: 592-598.
4. Lanier, L. L., C. Chang, and J. H. Phillips. 1994. Human NKR-P1A: a disulfide-linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes. J Immunol. 153: 2417-2428.
5. Exley, M., S. Porcelli, M. Furman, J. Garcia, and S. Balk. 1998. CDI61 (NKR-P1A) costimulation of CD1d-dependent activation of human T cells expressing invariant Vα24JαQ T cell receptor α chains. J. Exp. Med. 188: 867-876.
6. Godfrey, D. I., and M. Kronenberg. 2004. Going both ways: immune regulation via CD1d-dependent NKT cells. J. Clin. Invest. 114: 1379-1388.
7. Kung, S. K. P., R.-C. Su, J. Shannon, and R. G. Miller. 1999. The NKR-P1B gene product is an inhibitory receptor on SJL/J NK cells. J. Immunol. 162: 5876-5887.
8. Ryan, J., E. Niemi, M. Nakamura, and W. Seaman. 1995. NKR-P1A is a target-specific receptor that activates natural killer cell cytotoxicity. J. Exp. Med. 181: 1911-1915.
9. Iizuka, K., O. V. Naidenko, B. F. Plougastel, D. H. Fremont, and W. M. Yokoyama. 2003. Genetically linked C-type lectin-related ligands for the NKRP1 family of natural killer cell receptors. Nat. Immunol. 4: 801-807.
10. Carlyle, J. R., A. M. Jamieson, S. Gasser, C. S. Clingan, H. Arase, and D. H. Raulet. 2004. Missing self-recognition of Oci1/Clr-b by inhibitory NKR-P1 natural killer cell receptors. Proc. Natl. Acad. Sci. USA 101: 3527-3532.
11. + immature thymocytes: NKRP1A-mediated regulation of proliferation and cytolytic activity. Eur. J. Immunol. 26: 1266-1272.
12. lck via cysteine residues. Eur. J. Immunol. 27: 802.
13. Al-Aoukaly, A., B. Rolstad, and A. A. Maghazachi. 1997. Functional coupling of NKR-P1 receptors to various heterotrimeric G proteins in rat interleukin-2-activated natural killer cells. J. Biol. Chem. 272: 31604-31608.
14. Ljutic, B., J. R. Carlyle, D. Filipp, R. Nakagawa, M. Julius, and J. C. Zuniga-Pilucker. 2005. Functional requirements for signaling through the stimulatory and inhibitory mouse NKR-P1 (CD161) NK cell receptors. J. Immunol. 174: 4789-4796.
15. + T cells. J. Exp. Med. 186: 1957-1963.
16. Carlyle, J., A. Martin, A. Mehra, L. Attisano, F. Tsui, and J. Zuñiga-Pflucker. 1999. Mouse NKR-P1B, a novel NK1.1 antigen with inhibitory function. J. Immunol. 162: 5917-5923.
17. Cerný, J., A. Fiserova, O. Horvath, K. Bezouska, M. Pospisil, and V. Horejsi. 1997. Association of human NK cell surface receptors NKR-P1 and CD94 with Src-family protein kinases. Immunogenetics 46: 231-236.
18. Yodoi, J., K. Teshigawara, T. Nikaido, K. Fukui, T. Noma, T. Honjo, M. Takigawa, M. Sasaki, N. Minato, and M. Tsudo. 1985. TCGF (IL-2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J. Immunol. 134: 1623-1630.
19. Mandelboim, O., H. Reyburn, M. Valés-Gómez, L. Pazmany, M. Colonna, G. Borsellino, and J. Strominger. 1996. Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules. J. Exp. Med. 184: 913-922.
20. Davodeau, F., M. A. Peyrat, A. Necker, R. Dominici, F. Blanchard, C. Leget, J. Gaschet, P. Costa, Y. Jacques, A. Godard, et al. 1997. Close phenotypic and functional similarities between human and murine αβ T cells expressing invariant TCR α-chains. J. Immunol. 158: 5603-5611.
21. Cohen, G. B., R. T. Gandhi, D. M. Davis, O. Mandelboim, B. K. Chen, J. L. Strominger, and D. Baltimore. 1999. The selective downregulation of class 1 major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 10: 661-671.
22. Wiegmann, K., S. Schutze, T. Machleidt, D. Witte, and M. Kronke. 1994. Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor signaling. Cell 78: 1005-1015.
23. Hurwitz, R., K. Ferlinz, and K. Sandhoff. 1994. The tricyclic antidepressant desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts. Biol. Chem. Hoppe Seyler 375: 447-450.
24. Jaffrézou, J.-P., J.-M. Herbert, T. Levade, M.-N. Gau, P. Chatelain, and G. Laurent. 1991. Reversal of multidrug resistance by calcium channel blocker SR33557 without photoaffinity labeling of P-glycoprotein, J. Biol. Chem. 266: 19858-19864.
25. Mathias, S., A. Younes, C. C. Kan, I. Orlow, C. Joseph, and R. N. Kolesnick. 1993. Activation of the sphingomyelin signaling pathway in intact EL4 cells and in a cell-free system by IL-1β. Science 259: 519-522.
26. Alessi, D. R., M. Andjelkovic, B. Caudwell, P. Cron, N. Morrice, P. Cohen, and B. A. Hemmings. 1996. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 15: 6541-6551.
27. Boucher, L. M., K. S. Wiegmann, A. Futterer, K. Pfeffer, T. Machleidt, S. Schütze, T. W. Mak, and M. Krönke. 1995. CD28 signals through acidic sphingomyelinase. J. Exp. Med. 181: 2059-2068.
28. Adam, D., M. Heinrich, D. Kabelitz, and S. Schütze. 2002. Ceramide: does it matter for T cells? Trends Immunol. 23: 1-4.
29. Kolesnick, R. N., and M. Krönke. 1998. Regulation of ceramide production and apoptosis. Annu. Rev. Physiol. 60: 643-665.
30. Hannun, Y. A., C. Luberto, and K. M. Argraves. 2001. Enzymes of sphingolipid metabolism: from modular to integrative signaling. Biochemistry 40: 4893-4903.
31. Ruvolo, P. P. 2003. Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacol. Res. 47: 383-392.
32. Su, X., P. Wang, A. Ibitayo, and K. N. Bitar. 1999. Differential activation of pho.sphoinositide 3-kinase by endothelin and ceramide in colonic smooth muscle cells. Am. J. Physiol. 276: G853-G861.
33. ras, and phosphatidylinositol 3-kinase. J. Biol. Chem. 274: 12722-12729.
34. Monick, M. M., R. K. Mallampalli, A. B. Carter, D. M. Flaherty, D. McCoy, P. K. Robeff, M. W. Peterson, and G. W. Hunninghake. 2001. Ceramide regulates lipopolysaccharide-induced phosphatidylinositol 3-kinase and Akt activity in human alveolar macrophages. J. Immunol. 167: 5977-5985.
35. Bourbon, N. A., L. Sandirasegarane, and M. Kester. 2002. Ceramide-induced inhibition of Akt is mediated through protein kinase Cζ: implications for growth arrest. J. Biol. Chem. 277: 3286-3292.
36. Sato, S., N. Fujita, and T. Tsuruo. 2000. Modulation of Akt kinase activity by binding to Hsp90. Proc. Natl. Acad. Sci. USA 97: 10832-10837.
37. Sturgill, T. W., L. B. Ray, E. Erikson, and J. L. Mailer. 1988. Insulin-stimulated MAP-2 kinase phosphorylates and activates ribosomal protein S6 kinase II. Nature 334: 715-718.
38. Frödin, M., and S. Gammeltoft. 1999. Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol. Cell. Endocrinol. 151: 65-77.
39. Kolch, W. 2000. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem. J. 351(Pt. 2): 289-305.
40. Morrison, D. K., and R. J. Davis. 2003. Regulation of MAP kinase signaling modules by scaffold proteins in mammals. Annu. Rev. Cell Dev. Biol. 19: 91-118.
41. Bourbon, N. A., J. Yun, D. Berkey, Y. Wang, and M. Kester. 2001. Inhibitory actions of ceramide upon PKC-δ/ERK interactions. Am. J. Physiol. 280: C1403-C1411.
42. Liu, P., and R. G. W. Anderson. 1995. Compartmentalized production of ceramide at the cell surface. J. Biol. Chem. 270: 27179-27185.
43. Veldman, R. J., N. Maestre, O. M. Aduib, J. A. Medin, R. Salvayre, and T. Levade. 2001. A neutral sphingomyelinase resides in sphingolipid-enriched microdomains and is inhibited by the caveolin-scaffolding domain: potential implications in tumour necrosis factor signalling. Biochem. J. 355: 859-868.
44. Brown, D. A., and J. K. Rose. 1992. Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical cell surface. Cell 68: 533-544.
45. Smart, E. J., G. A. Graf, M. A. McNiven, W. C. Sessa, J. A. Engelman, P. E. Scherer, T. Okamoto, and M. P. Lisanti. 1999. Caveolins, liquid-ordered domains, and signal transduction. Mol. Cell. Biol. 19: 7289-7304.
46. Cremesti, A. E., F. M. Goni, and R. Kolesnick. 2002. Role of sphingomyelinase and ceramide in modulating rafts: do biophysical properties determine biologic outcome? FEBS Lett. 531: 47-53.
47. Dohrowsky, R. T. 2000. Sphingolipid signalling domains floating on rafts or buried in caves? Cell. Signal. 12: 81-90.
48. Rodgers, W., B. Crise, and J. K. Rose. 1994. Signals determining protein tyrosine kinase and glycosyl-phosphatidylinositol-anchored protein targeting to a glycolipid-enriched membrane fraction. Mol. Cell. Biol. 14: 5384-5391.
49. Grassmé, H., A. Cremesti, R. Kolesnick, and E. Gulbins. 2003. Ceramide-mediated clustering is required for CD95-DISC formation. Oncagene 22: 5457-5470.
50. Grassmé, H., A. Jekle, A. Riehle, H. Schwarz, J. Berger, K. Sandhoff, R. Kolesnick, and E. Gulbins. 2001. CD95 signaling via ceramide-rich membrane rafts. J. Biol. Chem. 276: 20589-20596.
51. Grassmé, H., V. Jendrossek, J. Bock, A. Riehle, and E. Gulbins. 2002. Ceramide-rich membrane rafts mediate CD40 clustering. J. Immunol. 168: 298-307.
52. Krönke. M. 1999. Biophysics of ceramide signaling: interaction with proteins and phase transition of membranes. Chem. Phys. Lipids 101: 109-121.
53. Chang, C., A. Rodriguez, M. Carretero, M. López-Botet, J. H. Phillips, and L. L. Lanier. 1995. Molecular characterization of human CD94: a type II membrane glycoprotein related to the C-type lectin superfamily. Eur. J. Immunol. 25: 2433-2437.
54. O'Byrne, D., and D. Sansom. 2000. Lack of costimulation by both sphingomyelinase and C2 ceramide in resting human T cells. Immunology 100: 225-230.
55. Kaga, S., S. Ragg, K. A. Rogers, and A. Ochi. 1998. Activation of p21-CDC42/ Rac-activated kinases by CD28 signaling: p21-activated kinase (PAK) and MEK kinase 1 (MEKK1) may mediate the interplay between CD3 and CD28 signals. J. Immunol. 160: 4182-4189.
56. Franke, T. F., and L. C. Cantley. 1997. Apoptosis: a bad kinase makes good. Nature 390: 116-117.
57. Bonni, A., A. Brunet, A. E. West, S. R. Datta, M. A. Takasu, and M. E. Greenberg. 1999. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286: 1358-1362.
58. Shimamura, A., B. A. Ballif, S. A. Richards, and J. Blenis. 2000. Rsk1 mediates a MEK-MAP kinase cell survival signal. Curr. Biol. 10: 127-135.
59. Ni, H.-T., M. J. Deeths, W. Li, D. L. Mueller, and M. F. Mescher. 1999. Signaling pathways activated by leukocyte function-associated Ag-1-dependent costimulation. J. Immunol. 162: 5183-5189.
60. Duckworth, B. C., and L. C. Cantley. 1997. Conditional inhibition of the mitogen-activated protein kinase cascade by wortmannin: dependence on signal strength. J. Biol. Chem. 272: 27665-27670.
61. Wennström, S., and J. Downward. 1999. Role of phosphoinositide 3-kinase in activation of ras and mitogen-activated protein kinase by epidermal growth factor. Mol. Cell. Biol. 19: 4279-4288.
62. Higuchi, M., S. Singh, J. P. Jaffrezou, and B. B. Aggarwal. 1996. Acidic sphingomyelinase-generated ceramide is needed but not sufficient for TNF-induced apoptosis and nuclear factor-κB activation. J. Immunol. 157: 297-304.
63. van Blitterswijk, W. J., A. H. van der Luit, R. J. Veldman, M. Verheij, and J. Borst. 2003. Ceramide: second messenger or modulator of membrane structure and dynamics? Biochem. J. 369: 199-211.
64. Nix, M., and W. Stoffel. 2000. Perturbation of membrane microdomains reduces mitogenic signaling and increases susceptibility to apoptosis after T cell receptor stimulation. Cell Death Differ. 7: 413-424.
65. Lozano, J., A. Morales, A. Cremesti, Z. Fuks, J. L. Tilly, E. Schuchman, E. Gulbins, and R. Kolesnick. 2001. Niemann-Pick Disease versus acid sphingomyelinase deficiency. Cell Death Differ. 8: 100-103.
66. Abdel Shakor, A. B., K. Kwiatkowska, and A. Sobota. 2004. Cell surface ceramide generation precedes and controls FcγRII clustering and phosphorylation in rafts. J. Biol. Chem. 279: 36778-36787.
67. Garcia-Barros, M., D. Lacorazza, H. Petrie, A. Haimovitz-Friedman, C. Cardon-Cardo, S. Nimer, Z. Fuks, and R. Kolesnick. 2004. Host acid sphingomyelinase regulates microvascular function not tumor immunity. Cancer Res. 64: 8285-8291.
68. Kolesnick, R. 2002. The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J. Clin. Invest. 110: 3-8.